Insulin-Like Growth Factor 2 Drives Fibroblast-Mediated Tumor Immunoevasion and Confers Resistance to Immunotherapy

Using mice with systemic or fibroblast-specific deletion of insulin-like growth factor 2 (IGF2), scientists demonstrated that IGF2 deficiency enhanced the infiltration and cytotoxic activity of CD8+ T cells, leading to a reduction in tumor burden.